Vancouver, British Columbia, December 21, 2007 – Protox Therapeutics Inc. (TSX-V: PRX), a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases, announced today that it has granted 585,000 options pursuant to its previously approved stock option plan. 150,000 of these options were granted with an exercise price of $0.90 and will vest over two years. The Company has also granted a total of 300,000 and 135,000 options, at exercise prices of $0.76 and $0.80 respectively, which will vest over three years.
